201. Prognostic Value of Pulmonary Hypertension, Right Ventricular Function and Tricuspid Regurgitation on Mortality After Transcatheter Mitral Valve Repair
- Author
-
Frank Meijerink, Samme M. de Witte, Jacqueline Limpens, Robbert J. de Winter, Berto J. Bouma, Jan Baan, Cardiology, Graduate School, ACS - Atherosclerosis & ischemic syndromes, ACS - Heart failure & arrhythmias, ACS - Pulmonary hypertension & thrombosis, and APH - Aging & Later Life
- Subjects
Pulmonary and Respiratory Medicine ,Predictors ,Hypertension, Pulmonary ,Ventricular Dysfunction, Right ,Mitral Valve Insufficiency ,Prognosis ,Right ventricular function ,Tricuspid Valve Insufficiency ,Pulmonary hypertension ,Treatment Outcome ,Ventricular Function, Right ,Humans ,Mitral Valve ,Cardiology and Cardiovascular Medicine ,Tricuspid - Abstract
Background: Pulmonary hypertension (PH), right ventricular (RV) dysfunction, and tricuspid regurgitation (TR) are commonly present in patients with mitral regurgitation (MR) and known to impair prognosis. This systematic review and meta-analysis aimed to determine the prognostic value of PH, RV function, and TR on mortality after transcatheter mitral valve repair (TMVR). Methods: A systematic search was performed to identify studies investigating PH, RV function, or TR in patients who underwent TMVR. Studies were included for pooled analysis if hazard ratios (HR) for all-cause mortality were given. Results: A total of 8,672 patients from 21 selected studies were included (PH, 11 studies; RV function, nine studies; TR, 10 studies). Mean follow-up was 2.7±1.6 years. The HRs and 95% CIs for all-cause mortality of PH (dichotomised: HR 1.70, 95% CI 1.00–2.87; per 10 mmHg increase in systolic PAP: HR 1.17, 95% CI 1.07–1.29), RV function (dichotomised: HR 1.86, 95% CI 1.45–2.38; per 5 mm decrease in TAPSE: HR 1.18, 95% CI 0.97–1.43) and TR (HR 1.51, 95% CI 1.28–1.79) indicated a significant association. Conclusion: Prognosis after TMVR is worse in patients with significant MR when concomitant PH, RV dysfunction, or TR are present. Careful assessment of these parameters should therefore precede clinical decision-making for TMVR. The current results encourage investigation into whether (1) intervention at an earlier stage of MR reduces incidence of PH, RV dysfunction, and TR; and (2) transcatheter treatment of concomitant TR can improve clinical outcome and prognosis for these patients.
- Published
- 2022
- Full Text
- View/download PDF